| Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq I Tirosh, B Izar, SM Prakadan, MH Wadsworth, D Treacy, JJ Trombetta, ... Science 352 (6282), 189-196, 2016 | 3867 | 2016 |
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ... Nature 487 (7408), 500-504, 2012 | 1954 | 2012 |
| Defining T cell states associated with response to checkpoint immunotherapy in melanoma M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ... Cell 175 (4), 998-1013. e20, 2018 | 1380 | 2018 |
| Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine LT Geller, M Barzily-Rokni, T Danino, OH Jonas, N Shental, D Nejman, ... Science 357 (6356), 1156-1160, 2017 | 1321 | 2017 |
| A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade L Jerby-Arnon, P Shah, MS Cuoco, C Rodman, MJ Su, JC Melms, ... Cell 175 (4), 984-997. e24, 2018 | 1027 | 2018 |
| BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma DT Frederick, A Piris, AP Cogdill, ZA Cooper, C Lezcano, CR Ferrone, ... Clinical cancer research 19 (5), 1225-1231, 2013 | 993 | 2013 |
| Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF R Haq, J Shoag, P Andreu-Perez, S Yokoyama, H Edelman, GC Rowe, ... Cancer cell 23 (3), 302-315, 2013 | 844 | 2013 |
| Resistance to checkpoint blockade therapy through inactivation of antigen presentation M Sade-Feldman, YJ Jiao, JH Chen, MS Rooney, M Barzily-Rokni, ... Nature communications 8 (1), 1136, 2017 | 808 | 2017 |
| Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma N Auslander, G Zhang, JS Lee, DT Frederick, B Miao, T Moll, T Tian, ... Nature medicine 24 (10), 1545-1549, 2018 | 579 | 2018 |
| Toward minimal residual disease-directed therapy in melanoma F Rambow, A Rogiers, O Marin-Bejar, S Aibar, J Femel, M Dewaele, ... Cell 174 (4), 843-855. e19, 2018 | 573 | 2018 |
| A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors DJ Konieczkowski, CM Johannessen, O Abudayyeh, JW Kim, ZA Cooper, ... Cancer discovery 4 (7), 816-827, 2014 | 542 | 2014 |
| The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies L Lin, AJ Sabnis, E Chan, V Olivas, L Cade, E Pazarentzos, S Asthana, ... Nature genetics 47 (3), 250-256, 2015 | 531 | 2015 |
| MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition N Wagle, EM Van Allen, DJ Treacy, DT Frederick, ZA Cooper, ... Cancer discovery 4 (1), 61-68, 2014 | 527 | 2014 |
| Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, ... Nature communications 7 (1), 10582, 2016 | 515 | 2016 |
| A melanocyte lineage program confers resistance to MAP kinase pathway inhibition CM Johannessen, LA Johnson, F Piccioni, A Townes, DT Frederick, ... Nature 504 (7478), 138-142, 2013 | 483 | 2013 |
| Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy MT Chow, AJ Ozga, RL Servis, DT Frederick, JA Lo, DE Fisher, ... Immunity 50 (6), 1498-1512. e5, 2019 | 474 | 2019 |
| Targeted next generation sequencing identifies markers of response to PD-1 blockade DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ... Cancer immunology research 4 (11), 959-967, 2016 | 472 | 2016 |
| BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice C Liu, W Peng, C Xu, Y Lou, M Zhang, JA Wargo, JQ Chen, HS Li, ... Clinical cancer research 19 (2), 393-403, 2013 | 402 | 2013 |
| sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance A Kaur, MR Webster, K Marchbank, R Behera, A Ndoye, CH Kugel, ... Nature 532 (7598), 250-254, 2016 | 357 | 2016 |
| Oncogenic BRAF (V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma JS Khalili, S Liu, TG Rodríguez-Cruz, M Whittington, S Wardell, C Liu, ... Clinical Cancer Research 18 (19), 5329-5340, 2012 | 326 | 2012 |
